| Name | Title | Contact Details |
|---|---|---|
John Langton |
Chief Technology Officer | Profile |
John Langton |
Chief Technology Officer | Profile |
Doran Smestad |
Senior Director of Security and Systems Engineering | Profile |
Raytel Medical Corporation is a Windsor, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Formed by revenue cycle industry leaders, Currance is a Rev-Cycle Performance solutions company focused on empowering community providers, physician practices and healthcare systems to achieve and sustain yield performance improvement. Currance`s strategy of Performance Partnering supports your own team by offering everything needed to drive yield performance: an intelligent technology platform that integrates with existing systems, tailored solutions, and professional services for operationalizing the technology and sustaining exceptional results. The Currance approach encompasses best-in-class knowledge of revenue cycle management, proprietary technologies, and the proven ability to engage, train, and mentor employees, adding value to clients` organizations. We embrace a mindset rooted in science and operational experience, enabling highly efficient processes and precise workflow design that improve profitability and help build patient-centered, high-performing organizations.
Helmer Scientific is an established, entrepreneurial, growth company headquartered in Noblesville, Indiana. We design, integrate, manufacture, market, and distribute specialized medical and laboratory equipment to clinical and life science customers in over 125 countries.
Transonic Systems is a Ithaca, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RaNA Therapeutics is pioneering the discovery of a new class of RNA-targeted medicines that selectively activate protein expression within the body`s own cells. By targeting specific genes, RaNA`s novel drugs work epigenetically to precisely upregulate the expression of beneficial proteins in order to treat or prevent disease. The company`s leadership leverages preeminent founders and advisors in the field, and the strength of its fundamental patents, technology, and know-how that underlie the discovery and development of therapeutics that selectively activate RNA. RaNA is applying its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, inflammation, oncology, metabolic diseases and neurodegenerative diseases.